July 14, 2026: Venture capital is flowing back into biotech, but investors are becoming far more selective about where they place their bets.
Biotech startups raised more than $9.1 billion across at least 68 venture-backed companies during the first six months of 2026, marking the strongest first-half fundraising performance since 2022. The recovery comes amid improving IPO markets, a pickup in mergers and acquisitions, and renewed investor confidence in the sector.
However, the capital isn’t being distributed evenly.
Most of the funding is going to companies that have already crossed an important milestone—moving a drug candidate into human clinical trials. According to industry data, nearly two-thirds of all funded companies in the first half already had medicines in clinical testing, highlighting investors’ growing preference for lower-risk opportunities over early-stage research.
Biotech VC Rebounds, Megarounds Dominate Market
Large financing rounds continue to define the biotech funding landscape. Roughly three-quarters of the total capital raised came from funding rounds worth $100 million or more, underlining the industry’s reliance on a handful of blockbuster investments.
One of the biggest contributors was AI-driven drug discovery company Isomorphic Labs, which secured a massive $2.1 billion funding round. While the deal significantly boosted overall fundraising figures, analysts note that excluding such outsized transactions, investment activity remains concentrated around more mature biotech businesses.
Another factor encouraging venture investors has been the rebound in biotech public listings.
The first half of 2026 witnessed 13 biotech IPOs raising a combined $4.5 billion, with median proceeds reaching roughly $302 million—well above historical averages. Several newly listed companies have also continued trading above their IPO prices, reinforcing confidence that venture-backed firms have viable exit opportunities.
A healthier IPO market has historically encouraged venture firms to deploy more capital, as successful listings improve the prospects of future returns.
Acquisition activity has also strengthened considerably this year.
Nearly 38 biotech acquisitions have been announced so far in 2026, putting the industry on track for one of its busiest years for mergers and acquisitions in recent history. Almost two-thirds of those transactions were valued at $1 billion or more, while four deals exceeded the $10 billion mark.
The surge suggests large pharmaceutical companies remain willing to acquire promising biotech assets despite broader economic uncertainty.
Early-stage innovation remains under pressure
While funding totals paint an optimistic picture, industry experts caution that the recovery masks a widening gap between established startups and emerging innovators.
Seed-stage companies and startups led by first-time founders continue to face a difficult fundraising environment compared with the investment boom seen several years ago.
The slowdown has also raised concerns about the long-term innovation pipeline, particularly as reductions in U.S. government research funding could eventually limit the number of breakthrough therapies entering development.
Rather than backing early scientific discoveries, many investors are increasingly financing companies built around drug candidates already developed elsewhere, including licensed assets from China and other international markets.
Investors favour proven therapeutic areas
Capital allocation also reveals changing investor preferences.
Companies developing cancer and immunology therapies accounted for more than 40% of funding rounds during the first half of the year, making them the clear favourites among venture investors.
Developers of biologics and small-molecule drugs each attracted more than $2 billion in funding, comfortably outperforming cell therapy, gene therapy and nucleic acid-focused companies.
By contrast, cell and gene therapy startups continue to experience sluggish investment levels, extending a trend that has persisted since 2022. Analysts attribute the cautious sentiment to commercial challenges facing recently launched therapies, safety concerns in clinical trials and continued regulatory uncertainty.
The first half of 2026 signals that investor confidence has returned to biotechnology but with a sharper focus on execution and clinical progress rather than early scientific promise.
For venture capital firms, companies with validated platforms, experienced leadership teams and assets already advancing through clinical development remain the preferred destination for capital. Meanwhile, the biggest challenge for the industry may lie in ensuring the next generation of breakthrough startups has access to the funding needed to reach that stage.
